ReviewZeitschrift fur Rheumatologie2026
[Autoimmunity and ageing : How immune ageing shapes disease phenotype, infection risk and treatment safety in rheumatic diseases].
Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune ageing alters tolerance mechanisms, the chronic low-grade inflammatory environment and host infection defence. This is clinically relevant in rheumatology because the number of older patients with inflammatory rheumatic diseases is increasing and age modifies disease phenotype, vaccination responses and treatment safety.
objectiveTo summarize the interfaces between ageing, autoimmunity and chronic inflammation and to derive consequences for prevention and treatment. MATERIAL AND
methodsNarrative review of recent reviews and key studies on immunosenescence, geroscience, autoimmunity, infection risk, vaccination responses and translational biomarkers.
resultsKey features include loss of naïve lymphocytes, repertoire contraction, inflammaging, myeloid dysregulation and disorders of cellular homeostasis. Classical autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) show features of premature immune ageing, whereas giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) illustrate age-restricted inflammatory disease. Clinically, immune ageing translates into altered susceptibility to infection, weaker responses to vaccination and a narrower safety margin during immunosuppression.
conclusionAge should be regarded as a biological modifier in rheumatic diseases. Clinical implications include early vaccination and infection prevention, glucocorticoid-sparing treatment strategies and biomarker-guided approaches that capture immunological rather than chronological age.
Indexed as
Identifiers
42429930What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.